Compare CXAI & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXAI | KYNB |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 27.1M |
| IPO Year | 2020 | 2014 |
| Metric | CXAI | KYNB |
|---|---|---|
| Price | $3.87 | $7.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.8M | 7.9K |
| Earning Date | 05-19-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9552.08 |
| EPS | ★ N/A | N/A |
| Revenue | $4,583,000.00 | ★ $6,440,000.00 |
| Revenue This Year | $33.54 | N/A |
| Revenue Next Year | $116.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.09 | $6.32 |
| 52 Week High | $4.88 | $9.58 |
| Indicator | CXAI | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 82.36 | 58.76 |
| Support Level | $0.23 | $6.61 |
| Resistance Level | N/A | $7.41 |
| Average True Range (ATR) | 0.21 | 0.30 |
| MACD | 0.47 | 0.04 |
| Stochastic Oscillator | 78.29 | 77.02 |
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. Its cloud-based, mobile-first platform integrates artificial intelligence, automation, and real-time analytics to streamline workplace interactions across people, spaces, and technology. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, Agentic AI Capabilities, and CXAI-VU. The company generates the majority of its revenue from Licenses.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.